Rezvani Maziar, Bernstein David I
Division of Allergy/Immunology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0563, USA.
Immunol Allergy Clin North Am. 2007 May;27(2):295-307, viii. doi: 10.1016/j.iac.2007.03.010.
Subcutaneous immunotherapy (IT) with aeroallergen extracts is venerable treatment modality. The major risk associated with IT with commercial aeroallergen extracts is the uncommon occurrence of severe near-fatal or fatal anaphylaxis after injections. The objectives of this article are to review the reported incidences of severe anaphylaxis (near-fatal reactions and fatal reactions), define factors contributing to these events, and identify preventive measures that are likely to reduce or eliminate future fatal and near-fatal anaphylactic events. As with any treatment, anticipated benefits attributed to IT must be weighed against its potential risks.
使用气传变应原提取物进行皮下免疫疗法（IT）是一种古老的治疗方式。与使用市售气传变应原提取物进行IT相关的主要风险是注射后罕见的严重濒死或致命过敏反应。本文的目的是回顾已报道的严重过敏反应（濒死反应和致命反应）的发生率，确定导致这些事件的因素，并确定可能减少或消除未来致命和濒死过敏事件的预防措施。与任何治疗一样，必须权衡IT预期的益处与其潜在风险。
Zotero 插件